

**Comparison of COVID-19 outcomes among shielded and non-shielded populations:
A general population cohort study of 1.3 million**

Bhautesh D Jani,* Frederick K Ho,* David J Lowe, Sean MacBride-Stewart, Frances S Mair,
Jill P Pell

*Joint-first author

Bhautesh D Jani PhD
Clinical Senior Lecturer in General Practice and Primary Care
Institute of Health and Wellbeing, University of Glasgow,
Glasgow G12 9LX, UK
Bhautesh.jani@glasgow.ac.uk

Frederick K Ho PhD
Research Associate
Institute of Health and Wellbeing, University of Glasgow
Glasgow, G12 8RZ, UK
Frederick.Ho@glasgow.ac.uk

David J Lowe MSc
Consultant in Emergency Medicine,
Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde,
Glasgow, G52 4TF, UK
David.lowe@nhs.net

Sean MacBride-Stewart PhD
Lead Pharmacist (Medicines Management Resources)
Pharmacy Services
NHS Greater Glasgow and Clyde, G76 7AT, UK
Sean.MacBride-Stewart@ggc.scot.nhs.uk

Frances S Mair MD
Norie Miller Professor of General Practice
Institute of Health and Wellbeing, University of Glasgow,
Glasgow G12 9LX, UK
Frances.mair@glasgow.ac.uk

Jill P Pell MD
Henry Mechan Professor of Public Health
Institute of Health and Wellbeing, University of Glasgow,
Glasgow, G12 8RZ, UK
Jill.pell@glasgow.ac.uk

Supplementary Table 1. Criteria for high risk and moderate risk categories


High Risk	Moderate Risk
<p>Severe respiratory disease:</p> <ul style="list-style-type: none"> • severe COPD • severe asthma (high-dose steroids) • cystic fibrosis 	<p>Chronic respiratory disease:</p> <ul style="list-style-type: none"> • COPD • asthma • emphysema • bronchitis
<p>Specific cancers:</p> <ul style="list-style-type: none"> • Lung cancer plus radical radiotherapy or active chemotherapy • Blood or bone marrow cancers • Bone marrow or stem cell transplant <ul style="list-style-type: none"> ◦ in last 6 months, or ◦ still taking immunosuppressants • immunotherapy or continuing antibody treatment • protein kinase inhibitors or PARP inhibitors 	<p>Other chronic conditions</p> <ul style="list-style-type: none"> • heart disease/hypertension • diabetes • kidney disease • liver disease • neurological conditions
Pregnant with significant heart disease	Pregnant
Immunosuppressive therapy	<p>Weakened immune system due to:</p> <ul style="list-style-type: none"> • Medical condition • Medication (e.g. oral steroids, chemotherapy)
Solid organ transplant	BMI $\geq 40 \text{ kg/m}^2$
Relevant rare diseases and inborn errors of metabolism (e.g. SCID, homozygous sickle cell)	≥ 70 years of age
Renal dialysis	

Supplementary Table 2. Population attributable fractions for risk categories and risk criteria and COVID-19 outcomes

	Confirmed COVID-19		COVID-19 hospitalisation		COVID-19 ICU admission		COVID-19 Death	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
Moderate								
Overall	41.22	40.66-41.81	61.33	60.72-61.97	20.78	15.36-27.07	75.27	75.06-75.48
Chronic respiratory disease	3.50	3.22-3.75	5.08	4.78-5.36	0.90	-2.65-4.78	2.23	2.01-2.51
Heart disease	4.74	4.63-4.84	7.98	7.83-8.12	1.74	0.42-3.31	6.19	6.1-6.27
Hypertension	10.18	9.97-10.38	17.20	16.95-17.44	8.93	6.52-11.48	12.00	11.83-12.18
Diabetes	5.22	5.09-5.34	7.95	7.79-8.09	9.79	8.51-10.95	4.98	4.9-5.08
Weakened immune system	0.14	0.13-0.16	0.23	0.22-0.25	-	-	0.34	0.32-0.36
≥70 years of age	17.45	17.26-17.65	22.90	22.61-23.22	-	-	49.53	49.17-49.91
High								
Overall	8.58	8.4-8.75	15.45	15.13-15.75	4.91	3.7-6.3	13.38	13.2-13.54
Severe respiratory disease	0.39	0.37-0.43	5.74	5.57-5.9	-	-	0.56	0.53-0.59
Specific cancers	3.37	3.26-3.48	1.69	1.63-1.76	-	-	6.90	6.78-7
Immunosuppressive therapy	0.89	0.84-0.93	1.84	1.77-1.92	-	-	1.29	1.24-1.34
Solid organ transplant	1.41	1.36-1.48	0.77	0.72-0.82	-	-	2.00	1.95-2.07
Rare diseases and IEM	0.84	0.79-0.89	1.32	1.26-1.39	-	-	1.69	1.61-1.78
Renal dialysis	1.67	1.61-1.74	4.08	3.97-4.21	-	-	0.93	0.9-0.97

CI confidence interval; IEM inborn errors of metabolism

Supplementary Figure 1. Cumulative population attributable fractions (lines) and population prevalence (bars) for individual risk criteria



Brown – high risk criteria

Pale orange – medium risk criteria